<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546284</url>
  </required_header>
  <id_info>
    <org_study_id>HGEN003-05</org_study_id>
    <nct_id>NCT02546284</nct_id>
  </id_info>
  <brief_title>Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)</brief_title>
  <official_title>A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanigen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanigen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate
      safety, pharmacokinetics, and clinical activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to examine the safety and determine the recommended Phase 2 dose
      of lenzilumab when administered to subjects with previously treated CMML who meet the entry
      criteria. Study will begin enrollment in July 2016.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of lenzilumab (as measured by the number of participants with adverse events) at various doses in order to determine a recommended Phase 2 dose</measure>
    <time_frame>Up to an average of 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical activity of lenzilumab (as measured by changes in spleen size, blood and bone marrow measurements of disease, clinical symptoms, etc)</measure>
    <time_frame>Up to an average of 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration (Cmax) of lenzilumab</measure>
    <time_frame>At end of infusion or 1 hour after end of infusion on Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of lenzilumab</measure>
    <time_frame>Pre-dose to end of infusion or 1 hour after end of infusion on Day 1</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Minimum plasma concentration (Cmin) of lenzilumab</measure>
    <time_frame>At Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration curve (AUC) of lenzilumab</measure>
    <time_frame>Predose, end of infusion, 1 hour after end of infusion on Day 1, Day 2, Day 7, Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma half life (t ½) of lenzilumab</measure>
    <time_frame>End of infusion, 1 hour after end of infusion on Day 1, Day 2, Day 7, Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma clearance (CL) of lenzilumab</measure>
    <time_frame>End of infusion, 1 hour after end of infusion on Day 1, Day 2, Day 7, Day 15</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>lenzilumab immunogenicity (as measured by antibodies against lenzilumab in blood)</measure>
    <time_frame>Up to an average of 12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <arm_group>
    <arm_group_label>Single Agent lenzilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenzilumab</intervention_name>
    <arm_group_label>Single Agent lenzilumab</arm_group_label>
    <other_name>Monoclonal Antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CMML

          -  CMML that is refractory to, or progressed following treatment with a hypomethylating
             agent or other standard of care treatment

          -  Eastern Cooperative Oncology Group (ECOG) score ≤ 2

          -  Able to provide bone marrow biopsy samples

          -  Acceptable laboratory results

        Exclusion Criteria:

          -  Leukemia other than CMML

          -  Recent chemotherapy or radiation therapy (within 14 days before first dose of
             lenzilumab)

          -  Concurrent use of human granulocyte-macrophage colony-stimulating factor

          -  Pregnant or breastfeeding

          -  Know HIV virus infection

          -  History of another malignancy within the past 2 years (some skin cancer and prostate
             cancers permitted)

          -  Significant intercurrent illness

          -  History or current diagnosis of Pulmonary Alveolar Proteinosis or Hypoxemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian Lo</last_name>
    <phone>650-243-3182</phone>
    <email>alo@humanigen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariel Escobar, BS</last_name>
      <phone>813-745-7362</phone>
      <email>Mariel.Escobar@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>David Sallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Hirvela, BS</last_name>
      <phone>507-538-4212</phone>
      <email>hirvela.jeffrey@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mrinal Patnaik, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

